Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to novel pyrrolo[3,2-c]pyridine derivatives or phar ⁇ maceutically acceptable salts thereof which have an excellent inhibitory activity against gastric acid secretion, processes for the preparation thereof, and pharmaceutical compositions comprising the same.
• Peptic ulcer disease occurs when offensive factors involving gastric acid secretion are strong or defensive factors of gastric mucous are weak.
• various drugs such as antacid, anticholinergic agent, H -receptor antagonist, and proton pump inhibitor have been used.
• the advent of omeprazole as a proton pump inhibitor has rekindled research activities in this field.
• the present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharma ⁇ ceutically acceptable salts thereof, which have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.
• a pyrrolo[3,2-c] pyridine derivative or a pharmaceutically acceptable salt thereof there is provided a pyrrolo[3,2-c] pyridine derivative or a pharmaceutically acceptable salt thereof.
• a pharmaceutical composition comprising the pyrrolo[3,2-c]pyridine derivative or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
• R is hydrogen; a straight or branched C - C alkyl group, optionally substituted
• R 2 is hydrogen or a straight or branched C 1 - C6 alkyl group
• R 3 is hydrogen; a straight or branched C 1 - C6 alkyl group; a straight or branched C 2
• R 4 is a 1,2,3,4-tetrahydroisoquinolinyl group; a benzyloxy group optionally one or more substituted with halogen; or an amino group substituted with one or two sub ⁇ stituents selected from the group consisting of hydrogen, straight or branched C - C alkylcarbonyl, phenoxycarbonyl, benzyl optionally one or more substituted with halogen, and benzoyl optionally one or more substituted with halogen.
• R is hydrogen; a straight or branched C - C alkyl group; a C - C alkyl group
• 1 1 6 1 3 substituted with one or more substituents selected from the group consisting of methoxy , ethoxy, hydroxy, cyclopropyl, cyclobutyl, cyclohexyl, methylthiazolyl, and 1,3-dioxolanyl; a straight or branched C - C alkenyl group; a straight or branched C -
• R is a straight or branched C - C alkyl group
• R is hydrogen; a straight or branched C - C alkyl group; a straight or branched C
• R 4 is a 1,2,3,4-tetrahydroisoquinolinyl group; a benzyloxy group optionally one or more substituted with halogen; or an amino group substituted with one or two sub- stituents selected from the group consisting of hydrogen, straight or branched C - C alkylcarbonyl, phenoxycarbonyl, benzyl optionally one or more substituted with halogen, and benzoyl optionally one or more substituted with halogen.
• More preferred compounds of the formula (I) or its pharmaceutically acceptable salts of the present invention are:
• the compounds of the present invention may be pharmaceutically acceptable non ⁇ toxic salt forms.
• the non-toxic salts may include conventional acid addition salts used in the field of anti-ulcer agents, e.g., salts originated from inorganic acid such as hy ⁇ drochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, or nitric acid, and organic acid such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, citric acid, maleic acid, malonic acid, methanesulfonic acid, tartaric acid, malic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, 2-acetoxybenzoic acid, fumaric acid, p-toluenesulfonic acid, oxalic acid, or triflu- oroacetic acid.
• the non-toxic salts include conventional metal salt forms, e.g., salts originated from metal such as lithium
• the present invention includes, within its scope, a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in accordance with the following Scheme 1 :
• the compound of formula (I) or its pharmaceutically acceptable salt may be prepared using a process which comprises: (a) adding a sodium nitrite solution to a compound of formula (II), followed by reducing the resulting product with tin chloride, to obtain a compound of formula (HI); (b) reacting the compound of formula (IE) with a compound of formula (IV) to obtain a compound of formula (V); (c) performing a cyclization reaction of a compound of formula (V) to obtain a compound of formula (VI); (d) halogenizing the compound of formula (VI) to obtain a compound of formula (VII); (e) reacting the compound of formula (VII) with R 4 -H to obtain a compound of formula (Ia); and (f) reacting the compound of formula (Ia) with R -X to obtain a compound of formula (I).
• step (a) may be performed by adding a sodium nitrite solution at a temperature of -20 °C ⁇ 5°C to a solution of the compound of formula (II) in an inorganic acid, followed by reducing the resulting product with tin chloride.
• a compound of formula (V) may be prepared by reacting the compound of formula (III) with a compound of formula (IV) under heating, in an organic solvent, e.g., ethanol.
• the cyclization reaction of the compound of formula (V) may be performed in an organic solvent, e.g., diphenyl ether having a high boiling point. Further, the reaction may be carried out at a temperature of 100°C ⁇ 300°C.
• the compound of formula (VI) is halogenized to the compound of formula (VII), using various halogenizing agents, e.g., phosphorus oxychloride. Further, the halogenizing reaction may be performed at room temperature or at a temperature of 40
• the compound of formula (VII) is reacted with R 4 -H to obtain a compound of formula (Ia).
• the reaction of the compound of formula (VII) and R 4 -H may be performed in the presence of a base, such as sodium hydride, potassium terf-butoxide, sodium carbonate, or potassium hydroxide. Further, the reaction may be carried out in an organic solvent, such as tetrahydrofuran, ⁇ N-dimethylformamide, and toluene, and at room temperature or at a temperature of 40 °C ⁇ 100°C.
• the compound of formula (Ia) is reacted with R -X to finally obtain a compound of formula (I).
• the reaction of the compound of formula (Ia) and R -X may be performed in the presence of a base, such as sodium hydride or potassium terf-butoxide. Further, the reaction may be carried out in an organic solvent, such as tetrahydrofuran or N, N- dimethylformamide, and at room temperature or at a temperature of 40 °C ⁇ 100°C. In order to increase a reaction rate and/or a yield of the reaction, a catalytic amount of 18-crown-6 may be used.
• the present invention further includes, within its scope, a pharmaceutical composition comprising a therapeutically effective amount of any of the compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof and a phar ⁇ maceutically acceptable carrier.
• the compound of formula (I) or a pharmaceutically acceptable salt thereof may be used for prevention and treatment of gastrointestinal in ⁇ flammatory diseases and gastric acid-related diseases in mammals including human, such as gastritis, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome.
• the compounds or their salts of the present invention may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable, e.g. in patients with gastrinomas, and in patients with acute upper gas ⁇ trointestinal bleeding.
• the compounds or their salts of the present invention may also be used in patients in intensive care situations, and pre-and postoperatively to prevent acid aspiration and stress ulceration.
• composition of the present invention may include additives such as lactose or corn starch, lubricants such as magnesium stearate, emulsifiers, suspending agents, stabilizers, and isotonic agents. If necessary, sweetening agents and/or flavoring agents may be added.
• additives such as lactose or corn starch
• lubricants such as magnesium stearate, emulsifiers, suspending agents, stabilizers, and isotonic agents. If necessary, sweetening agents and/or flavoring agents may be added.
• composition of the present invention may be administered orally or par- enterally, including intravenous, intraperitoneal, subcutaneous, rectal and topical routes of administration. Therefore, the composition of the present invention may be formulated into various forms such as tablets, capsules, aqueous solutions or suspensions.
• carriers such as lactose, corn starch, and lubricating agents, e.g. magnesium stearate, are commonly added.
• lactose and/or dried corn starch can be used as a diluent.
• the active ingredient may be combined with emulsifying and/or suspending agents.
• composition of the present invention may be in the form of an aqueous solution containing pharmaceutically acceptable carriers, e.g., saline, at a pH level of 7.4.
• pharmaceutically acceptable carriers e.g., saline
• the compounds of the present invention may be administered in an effective amount ranging from about 0.1 mg/kg to about 500 mg/kg per day to a subject patient.
• the dosage may be changed according to the patient's age, weight, sus ⁇ ceptibility, or symptom.
• Step 2 4-(N- sec-butyliden-hydrazino)-lH-pyridin-2-one
• Step 3 2,3-dimethyl- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one
• Step 2 was added to diphenyl ether (200 ml ). The reaction mixture was refluxed under stirring for 5 hours and cooled to room temperature. n- ⁇ exane (200 ml ) was added under stirring to the reaction mixture, which was then filtered. The resulting solid was recrystallized with methanol (20 ml) to give the titled compound as a pale yellow solid. (Yield: 73.2 %)
• Step 4 4-chloro-2,3-dimethyl- lH-pyrrolo[3,2-c]pyridine
• Step 1 4-[N'-(l-methyl-3-phenyl-propylidene)-hydrazino]-lH-pyridin-2-one
• Step 1 4-[N'-(l-methyl-3-(3-fluorophenyl)-propylidene)-hydrazino]-l H - pyridin-2-one [162] In accordance with the same procedures as in Step 2 of Preparation 1, except for using 4-hydrazino-lH-pyridin-2-one (5.39 g, 43.1 mmol) prepared in Step 1 of
• Step 1 4- [N '-( 1 -methyl-pent-4-enylidene)-hydrazino] - lH-pyridin-2-one
• Example 33 2,3-dimethyl-4-(4-fluorobenzylamino)-lH-pyrrolo[3,2-c]pyridine hy ⁇ drochloride
• 2,3-dimethyl-4-(4-fluorobenzylamino)-lH-pyrrolo[3,2-c]pyridine (1.44 g, 5.34 mmol) prepared in Example 32 was dissolved in ethyl acetate (10 ml ). The reaction mixture was saturated with hydrochloric acid gas and then filtered to give the titled compound as a white solid. (Yield: 82.5%)
• Example 35 to 46 The titled compounds of Examples 35 to 46 were prepared, in accordance with the same procedures as in Example 34, using 2,3-dimethyl-4-(4-fluorobenzylamino)-lH - pyrrolo[3,2-c]pyridine prepared in Example 32; and, iodoethane, 1-iodopropane, allyl bromide, 2-bromopropane, l-bromo-2-methylpropane, (bromomethyl)cyclopropane, 2-bromoethyl methyl ether, 2-bromomethyl-l,3-dioxolane, benzyl bromide, 2-fluorobenzyl bromide, 3-fluorobenzyl bromide, or 4-fluorobenzyl bromide.
• Example 38 2,3-dimethyl-l-isopropyl-4-(4-fluorobenzylamino)-lH-pyrrolo[3,2-c] pyridine hydrochloride [265] ⁇ H-NMR (CDCl 3 ) ⁇ 7.73 (bra, IH), 7.49 (bra, 2H), 7.06 (bra, 2H), 6.96 (bra, IH),
• Example 40 l-cyclopropylmethyl-2,3-dimethyl-4-(4-fluorobenzylamino)-lH - pyrrolo[3,2-c]pyridine hydrochloride [269] ⁇ ⁇ -NMR (CDCl 3 ) ⁇ 7.79 (bra, 1 ⁇ ), 7.50 (bra, 2 ⁇ ), 7.07 (bra, 2H), 6.81 (bra, IH),
• Triethylamine (0.013 ml , 0.090 mmol) and acetyl chloride (0.006 ml , 0.090 mmol) were added to a solution of l,2,3-trimethyl-4-(4-fluorobenzylamino)-lH - pyrrolo[3,2-c]pyridine (17 mg, 0.060 mmol) in tetrahydrofuran (2 ml ).
• the reaction mixture was stirred for 30 minutes at room temperature and concentrated under reduced pressure.
• the resulting residue was purified with silica gel column chro ⁇ matography ( ethyl acetate ), dissolved in ethyl acetate (1 ml ), and then saturated with hydrochloric acid gas.
• Example 54 3-benzyl-2-methyl-4-(l,2,3,4-tetrahydroisoquinolin-2-yl)-lH - pyrrolo [3 ,2-c]pyridine [302] In accordance with the same procedures as Example 1, except for using
• Example 55 3-benzyl-2-methyl-4-(l,2,3,4-tetrahydroisoquinolin-2-yl)-lH - pyrrolo[3,2-c]pyridine hydrochloride [305] In accordance with the same procedures as Example 2, except for using
• Test Example 1 Inhibitory effects on proton pump (H + ZK + -ATPaSe) activity
• sucrose buffer and Ficoll solution After being centrifuged for 3 hours and 15 minutes at 100,000 x g, the material at the interface of sucrose buffer and Ficoll solution was collected and then centrifuged for 40 minutes at 100,000 x g. The resulting pellets were re-suspended in 1 ml of 5 mM Hepes/Tris buffer (pH 6.1). This material was lyophilized and stored at -70 °C and used as an enzyme source of the in vitro enzyme reaction assay of proton pump.
• T he inhibitory effects of the compounds of the present invention against proton pump activity were evaluated in 96-well plate.
• the K + specific H + ZK + - ATPase activity was calculated based on the difference between the activity of H + ZK + - ATPase activity with K + and without K + ion.
• DMSO dimethylsulf oxide
• reaction buffer containing 1% DMSO was added to the negative and positive control groups and to each concentration of compounds in the test group.
• lyophilized vesicle in 5mM Pipes/Tris buffer pH 6.1 was pre-incubated in the presence of various concentrations of test compounds. After a 5 minute incubation, negative and positive buffers were re ⁇ spectively added to the previous reaction mixture. As the substrate, ATP was added to the reaction buffer, and incubated for 30 minutes at 37°C.
• Enzymatic activity was stopped by the addition of colorimetric reagent (2X malachite green, IX ammonium molybdate, IX polyvinyl alcohol, 2X H O) and the amount of mono phosphate (Pi) in the reaction was measured at 620nm using the micro plate reader (Genios Pro, TECAN). The difference between the Pi production with K + and without K + is taken as K + stimulated H 4 TK + - ATPase activity. The IC s of test compounds were calculated from each % inhibition value of compounds using the method of Litchfield-Wilcoxon ( J. Pharmacol. Exp. Ther. (1949) 96, 99). The results are shown in Table 1.
• the compounds of the present invention have excellent inhibitory effects on gastric H + ZK + - ATPase .
• Test Example 2 Inhibitory effects on basal gastric acid secretion in pylorus-ligated rats
• % inhibitory activity of test compound (total acid output of control group - total acid output of the group treated with test compounds) / total acid output of control group X 100 [387] Table 2.
• the compounds of the present invention have potent inhibition activities against basal gastric acid secretion in pylorus-ligated rats.
• the protein content of gastric vesicles was determined by the Bradford method using bovine serum albumin as a standard (Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72, 248-254, 1976).
• test compounds on H + ZK + -ATPaSe was investigated according to the Washout method (Beil W, Staar U, and Sewing KF, Substituted thieno[3,4-d]imidazoles, a novel group of H + ZK + -ATPaSe inhibitors. Differentiation of their inhibition characteristics from those of omeprazole. EMr. J. Pharmacol, 187, 455-67, 1990).
• the su ⁇ pernatant thereof was replaced with the same buffer not having the test compound.
• the test sample was pre-incubated for 5 minutes at room temperature and then incubated further for 30 minutes at 37°C.
• the H + ZK + -ATPaSe activity was also measured using the colorimetric detection method.
• the H + ZK + -ATPaSe activity before washout and after washout in the test sample was analyzed, in comparison with those in the non- treated group.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Epidemiology (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=36000316

Family Applications (1)

Country Status (16)

Cited By (10)

Families Citing this family (2)

Citations (7)

Family Cites Families (5)

• 2005
  • 2005-09-03 CN CN200580029382XA patent/CN101018788B/zh not_active Expired - Fee Related
  • 2005-09-03 EP EP05781131A patent/EP1784402B1/en not_active Expired - Lifetime
  • 2005-09-03 ES ES05781131T patent/ES2367312T3/es not_active Expired - Lifetime
  • 2005-09-03 DK DK05781131.7T patent/DK1784402T3/da active
  • 2005-09-03 BR BRPI0514843-0A patent/BRPI0514843A/pt not_active Application Discontinuation
  • 2005-09-03 CA CA2578880A patent/CA2578880C/en not_active Expired - Fee Related
  • 2005-09-03 AT AT05781131T patent/ATE518858T1/de active
  • 2005-09-03 RU RU2007112108/04A patent/RU2378275C2/ru not_active IP Right Cessation
  • 2005-09-03 WO PCT/KR2005/002924 patent/WO2006025714A1/en not_active Ceased
  • 2005-09-03 KR KR1020050082008A patent/KR100946219B1/ko not_active Expired - Fee Related
  • 2005-09-03 MX MX2007002214A patent/MX2007002214A/es active IP Right Grant
  • 2005-09-03 JP JP2007529714A patent/JP5126830B2/ja not_active Expired - Fee Related
  • 2005-09-03 US US11/574,393 patent/US8148529B2/en not_active Expired - Fee Related
  • 2005-09-03 PT PT05781131T patent/PT1784402E/pt unknown
  • 2005-09-03 AU AU2005280738A patent/AU2005280738B2/en not_active Ceased
  • 2005-09-03 PL PL05781131T patent/PL1784402T3/pl unknown
• 2011
  • 2011-11-15 US US13/296,378 patent/US8513277B2/en not_active Expired - Fee Related

Patent Citations (7)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events